Global Information
회사소개 | 문의 | 비교리스트

세계의 바이오시밀러 시장 : 제품별, 용도별, 제조업체별, 기술별 시장 규모, 산업 분석, 지역별 전망, 용도별 잠재성, 신종 코로나바이러스 감염증(COVID-19)의 영향 분석, 경쟁 시장 점유율, 예측(2022-2030년)

Biosimilars Market Size By Product, By Application, By Manufacturer, By Technology Industry Analysis Report, Regional Outlook, Application Potential, COVID-19 Impact Analysis, Competitive Market Share & Forecast, 2022 - 2030

리서치사 Global Market Insights Inc.
발행일 2022년 06월 상품코드 1094969
페이지 정보 영문 650 Pages 배송안내 2-3일 (영업일 기준)
가격
US $ 5,150 ₩ 7,316,000 Unprintable PDF (Single User License)
US $ 7,150 ₩ 10,157,000 Printable PDF (Multi User License)
US $ 9,150 ₩ 12,998,000 Printable PDF (Enterprise User License)


세계의 바이오시밀러 시장 : 제품별, 용도별, 제조업체별, 기술별 시장 규모, 산업 분석, 지역별 전망, 용도별 잠재성, 신종 코로나바이러스 감염증(COVID-19)의 영향 분석, 경쟁 시장 점유율, 예측(2022-2030년) Biosimilars Market Size By Product, By Application, By Manufacturer, By Technology Industry Analysis Report, Regional Outlook, Application Potential, COVID-19 Impact Analysis, Competitive Market Share & Forecast, 2022 - 2030
발행일 : 2022년 06월 페이지 정보 : 영문 650 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 바이오시밀러 시장은 의료 시설에서의 비용 절감을 목적으로 한 바이오시밀러 수요 증가에 의해 2030년까지 지수함수적으로 성장할 것으로 예상됩니다.

제품별로는 재조합 비당화 단백질 분야가 분석기간 중에 약 15.4%의 견실한 CAGR로 확대될 것으로 예상됩니다. 용도별로는 당뇨병 분야가 14.2% 이상의 점유율을 차지하고, 예측기간 중 약 15.2%의 CAGR로 성장할 것으로 예측됩니다.

제조업체별로는 CRAMS 부문이 2030년까지 견실한 성장을 보일 것으로 보입니다. 한편 주요 기업은 자사 시설에서 제품을 제조하고 있기 때문에, 2021년에는 전체의 4분의 3 이상이 사내 제조 부문이 차지하고 있습니다.

기술별로는 단일클론항체 기술이 향후 몇 년간 약 13.9%의 CAGR로 성장할 전망입니다. 지역별로 보면 북미 시장이 2021년에 업계 전체 매출의 28% 이상을 차지하고 있습니다.

세계의 바이오시밀러(Biosimilars) 시장에 대해 분석했으며, 업계의 기본 구조와 매력, 기술·규제 환경, 주요 시장 성장 촉진·억제요인, 제품별·용도별·제조업체별·기술별·지역별 시장 동향 전망, 주요 기업 개요·실적·전략 등을 조사했습니다.

목차

제1장 분석 방법과 범위

제2장 주요 요약

제3장 바이오시밀러 업계 인사이트

  • 업계 세분화
  • 업계 상황(단위 : 100만 달러, 2017-2030년)
  • 업계에 대한 영향요인
    • 성장 촉진요인
    • 업계의 잠재적 위험과 과제
  • 성장 가능성 분석
  • COVID-19의 영향 분석
  • Porter's Five Forces 분석
  • 규제 상황
  • 상환 상황
  • 시장 분석 : SWOT
  • 미국의 바이오시밀러 보험 보상 범위(2021년)
  • 바이오시밀러 소송 상황
  • 바이오시밀러 제품 파이프라인 분석
  • 바이오시밀러 승인 시나리오(2017-2022년)
  • 생물제제 특허 만료 시나리오
  • 바이오시밀러 업계 진화
  • 바이오시밀러 인자 분석
  • 바이오시밀러 상황 : 국가별 분석
  • 주요 시장 성공요인
  • 바이오시밀러 사용에 관한 국제 정책
  • 경쟁 상황(2021년)
    • 경쟁 매트릭스 분석, 2021년
  • PESTEL 분석

제4장 바이오시밀러 시장 : 제품별

  • 부문별 주요 동향
  • 재조합 비당화 단백질
    • 시장 규모 : 지역별(단위 : 100만 달러, 2017-2030년)
    • 인간성장호르몬
    • 과립구집락자극인자(필그라스팀)
    • 인슐린
    • 인터페론
  • 재조합 당화 단백질
    • 에리스로포이에틴
    • 단일클론항체
    • 폴리트로핀
    • 저분자량 헤파린(LMWH)

제5장 바이오시밀러 시장 : 용도별

  • 부문별 주요 동향
  • 혈액질환
    • 호중구감소증
    • 빈혈
    • 기타
  • 종양
    • 폐암
    • 뇌종양
    • 유방암
    • 자궁경부암
    • 대장암
    • 백혈병
    • 기타
  • 자가면역질환
    • 관절염
    • 염증성 장질환(IBD)
    • 건선
    • 기타
  • 성장호르몬결핍증
  • 당뇨병
  • 기타

제6장 바이오시밀러 시장 : 제조업체별

  • 부문별 주요 동향
  • CRAMS(수탁 연구·제조 서비스)
  • 사내 제조

제7장 바이오시밀러 시장, 기술별

  • 부문별 주요 동향
  • 재조합 DNA 기술(rDNA 기술)
  • 단일클론항체(MAb) 기술

제8장 바이오시밀러 시장 : 지역별

  • 지역별 주요 동향
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 스페인
    • 이탈리아
    • 터키
    • 오스트리아
    • 벨기에
    • 불가리아
    • 체코
    • 덴마크
    • 핀란드
    • 그리스
    • 헝가리
    • 아일랜드
    • 네덜란드
    • 노르웨이
    • 루마니아
    • 슬로바키아
    • 슬로베니아
    • 스웨덴
    • 스위스
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 한국
    • 호주
    • 뉴질랜드
    • 싱가포르
    • 말레이시아

제9장 기업 개요

  • 경쟁 대시보드(2021년)
  • Biocon Ltd
  • Sandoz
  • Viatris
  • Bio-Thera Solutions
  • Pfizer
  • Dr. Reddy's Laboratories
  • Amgen Inc.
  • Teva Pharmaceuticals
  • Fresenius Kabi
  • Coherus Biosciences
  • Apobiologix
  • Biocad
  • Intas Pharma
  • Reliance Life Sciences
  • Celltrion
  • Zydus Cadila
  • Lupin Pharma
  • Samsung Bioepis
KSM 22.07.11

The global biosimilars market is expected to grow at an exponential rate through 2030 due to increasing demand for biosimilar drugs for saving costs at healthcare facilities.

Recently, key players have been increasingly collaborating with competitors to enhance their business standing, which has improved overall market dynamics. For instance, in February 2022, Biocon Biologics Ltd. (BBL), a Biocon subsidiary, inked an agreement to acquire Viatris Inc.'s biosimilars business in a $3.35 billion deal.

With the acquisition, Biocon Biologics aimed to offer one of the sector's largest and most comprehensive portfolios of commercialized biosimilars with the addition of a variety of commercially available insulins, immunology & oncology biosimilars, and several other biosimilar assets.

The biosimilars market has been bifurcated in terms of product, application, manufacturer, technology, and region.

Based on product, the industry has been divided into recombinant glycosylated proteins and recombinant non-glycosylated proteins. The human growth hormone segment of the recombinant non-glycosylated proteins registered a substantial market valuation of around $2800 million and is slated to expand at a robust CAGR of approximately 15.4% over the review timeline owing to increased biosimilar demand globally.

With respect to application, the biosimilars market has been classified into hematology, oncology, autoimmune disease, growth hormone deficiency, diabetes, and others. The diabetes segment accounted for more than 14.2% of the application market share and is projected to exhibit a positive CAGR of nearly 15.2% over the forecast period attributed to surging prevalence of the disease among the global population.

With regards to manufacturer, the market has been categorized into contract research and manufacturing services and in-house. In 2021, the biosimilars market share from the contract research and manufacturing services segment was worth over $6,900 million and is set to showcase robust growth through 2030. The biosimilars industry's top players manufacture their products in the warehouses they own, which has resulted in the in-house category contributing to over three-fourths of the market size in 2021.

Based on technology, the biosimilars industry has been divided into recombinant DNA technology (rDNA technology) and monoclonal antibodies (MAb) technology. The MAb technology is the most recent and cutting-edge method of producing biosimilars, and as a result, it is foreseen to experience a CAGR of around 13.9% over the forthcoming years.

From the regional standpoint, the North America biosimilars market accounted for more than 28% of the overall industry revenue in 2021 and is set to witness considerable growth through the forecast period pertaining to mounting FDA approvals of biosimilar drugs in the North American region.

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definitions
  • 1.2 Base estimates & working
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Biosimilars industry 360 degree synopsis, 2017-2030 (USD Million)
    • 2.1.1 Business trends
    • 2.1.2 Product trends
    • 2.1.3 Application trends
    • 2.1.4 Manufacturer trends
    • 2.1.5 Technology trends
    • 2.1.6 Regional trends

Chapter 3 Biosimilars Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2017-2030 (USD Million)
  • 3.3 Industry impact factors
    • 3.3.1 Growth drivers
      • 3.3.1.1 Strong product pipeline
      • 3.3.1.2 Rise in prevalence of chronic diseases across the globe
      • 3.3.1.3 Expiry of blockbuster biologics
      • 3.3.1.4 Cost-effectiveness of biosimilars
      • 3.3.1.5 Recent biosimilar product approvals in major countries
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 Availability of alternative medications
      • 3.3.2.2 Regulatory Uncertainty
      • 3.3.2.3 High developmental costs
      • 3.3.2.4 Complex manufacturing process
  • 3.4 Growth potential analysis
    • 3.4.1 By product
    • 3.4.2 By application
    • 3.4.3 By manufacturer
    • 3.4.4 By technology
  • 3.5 COVID-19 impact analysis
  • 3.6 PORTER's Analysis
  • 3.7 Regulatory landscape
    • 3.7.1 U.S.
    • 3.7.2 Canada
    • 3.7.3 Europe
    • 3.7.4 India
    • 3.7.5 Japan
    • 3.7.6 South Korea
    • 3.7.7 Australia
    • 3.7.8 Singapore
  • 3.8 Reimbursement landscape
    • 3.8.1 U.S.
    • 3.8.2 Europe
    • 3.8.3 Canada
    • 3.8.4 Australia
    • 3.8.5 New Zealand
  • 3.9 Market analysis
    • 3.9.1 Strength
    • 3.9.2 Weakness
    • 3.9.3 Opportunity
    • 3.9.4 Threat
  • 3.10 U.S. biosimilars insurance coverage, 2021
  • 3.11 Biosimilar litigation landscape
  • 3.12 Biosimilar product pipeline analysis
    • 3.12.1 Amgen
    • 3.12.2 Biocon
    • 3.12.3 Sandoz
    • 3.12.4 Celltrion
    • 3.12.5 Coherus BioSciences
    • 3.12.6 Fresenius Kabi
    • 3.12.7 Pfizer
    • 3.12.8 Lupin
    • 3.12.9 Samsung Bioepis
    • 3.12.10 Teva Pharmaceuticals
  • 3.13 Biosimilars approval scenario, 2017-2022
    • 3.13.1 U.S.
    • 3.13.2 Canada
    • 3.13.3 Europe
    • 3.13.4 India
    • 3.13.5 South Korea
    • 3.13.6 Australia
    • 3.13.7 New Zealand
    • 3.13.8 Singapore
    • 3.13.9 Malaysia
  • 3.14 Biologics patent expiry scenario
  • 3.15 Biosimilars industry evolution
  • 3.16 Biosimilars factor analysis
    • 3.16.1 Access
    • 3.16.2 Regulations
    • 3.16.3 Payer assessment and access
    • 3.16.4 Physician acceptance
    • 3.16.5 Patient acceptance
    • 3.16.6 Number of biosimilar approvals
  • 3.17 Biosimilars landscape - country analysis
    • 3.17.1 U.S.
    • 3.17.2 Europe
    • 3.17.3 China
    • 3.17.4 Japan
    • 3.17.5 India
    • 3.17.6 South Korea
  • 3.18 Key market success factors
  • 3.19 International policies on use of biosimilar drugs
    • 3.19.1 Interchangeability, Switching and Substitution
    • 3.19.2 Supply Side Policies
    • 3.19.3 Prescribing Incentives
  • 3.20 Competitive landscape, 2021
    • 3.20.1 Competitive matrix analysis, 2021
  • 3.21 PESTEL analysis

Chapter 4 Biosimilars Market, By Product

  • 4.1 Key segment trends
  • 4.2 Recombinant Non-Glycosylated Proteins
    • 4.2.1 Market size, by region, 2017-2030 (USD Million)
    • 4.2.2 Human Growth Hormone
      • 4.2.2.1 Market size, by region, 2017-2030 (USD Million)
    • 4.2.3 Granulocyte Colony-Stimulating Factor (Filgrastim)
      • 4.2.3.1 Market size, by region, 2017-2030 (USD Million)
    • 4.2.4 Insulin
      • 4.2.4.1 Market size, by region, 2017-2030 (USD Million)
    • 4.2.5 Interferon
      • 4.2.5.1 Market size, by region, 2017-2030 (USD Million)
      • 4.2.5.2 Alfa
        • 4.2.5.2.1 Market size, by region, 2017-2030 (USD Million)
      • 4.2.5.3 Beta
        • 4.2.5.3.1 Market size, by region, 2017-2030 (USD Million)
  • 4.3 Recombinant Glycosylated Proteins
    • 4.3.1 Market size, by region, 2017-2030 (USD Million)
    • 4.3.2 Erythropoietin
      • 4.3.2.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.2.2 Alfa
        • 4.3.2.2.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.2.3 Zeta
        • 4.3.2.3.1 Market size, by region, 2017-2030 (USD Million)
    • 4.3.3 Monoclonal Antibodies
      • 4.3.3.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.3.2 Infliximab
        • 4.3.3.2.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.3.3 Rituximab
        • 4.3.3.3.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.3.4 Adalimumab
        • 4.3.3.4.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.3.5 Trastuzumab
        • 4.3.3.5.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.3.6 Bevacizumab
        • 4.3.3.6.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.3.7 Etanercept
        • 4.3.3.7.1 Market size, by region, 2017-2030 (USD Million)
    • 4.3.4 Follitropin
      • 4.3.4.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.4.2 Alfa
        • 4.3.4.2.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.4.3 Beta
        • 4.3.4.3.1 Market size, by region, 2017-2030 (USD Million)
    • 4.3.5 Low Molecular Weight Heparin (LMWHs)
      • 4.3.5.1 Market size, by region, 2017-2030 (USD Million)

Chapter 5 Biosimilars Market, By Application

  • 5.1 Key segment trends
  • 5.2 Hematology
    • 5.2.1 Market size, by region, 2017-2030 (USD Million)
    • 5.2.2 Neutropenia
      • 5.2.2.1 Market size, by region, 2017-2030 (USD Million)
    • 5.2.3 Anemia
      • 5.2.3.1 Market size, by region, 2017-2030 (USD Million)
    • 5.2.4 Others
      • 5.2.4.1 Market size, by region, 2017-2030 (USD Million)
  • 5.3 Oncology
    • 5.3.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.2 Lung Cancer
      • 5.3.2.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.3 Brain Cancer
      • 5.3.3.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.4 Breast Cancer
      • 5.3.4.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.5 Cervical Cancer
      • 5.3.5.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.6 Colorectal Cancer
      • 5.3.6.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.7 Leukemia
      • 5.3.7.1 Market size, by region, 2017-2030 (USD Million)
      • 5.3.7.2 Non-Hodgkin Lymphoma (NHL)
        • 5.3.7.2.1 Market size, by region, 2017-2030 (USD Million)
      • 5.3.7.3 Chronic Lymphocytic Leukemia (CLL)
        • 5.3.7.3.1 Market size, by region, 2017-2030 (USD Million)
      • 5.3.7.4 Others
        • 5.3.7.4.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.8 Others
      • 5.3.8.1 Market size, by region, 2017-2030 (USD Million)
  • 5.4 Autoimmune Disease
    • 5.4.1 Market size, by region, 2017-2030 (USD Million)
    • 5.4.2 Arthritis
      • 5.4.2.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.2.2 Rheumatoid Arthritis
        • 5.4.2.2.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.2.3 Psoriatic Arthritis
        • 5.4.2.3.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.2.4 Juvenile Arthritis
        • 5.4.2.4.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.2.5 Ankylosing Spondylitis
        • 5.4.2.5.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.2.6 Others
        • 5.4.2.6.1 Market size, by region, 2017-2030 (USD Million)
    • 5.4.3 Inflammatory Bowel Disease (IBD)
      • 5.4.3.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.3.2 Ulcerative Colitis
        • 5.4.3.2.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.3.3 Crohn's Disease
        • 5.4.3.3.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.3.4 Others
        • 5.4.3.4.1 Market size, by region, 2017-2030 (USD Million)
    • 5.4.4 Psoriasis
      • 5.4.4.1 Market size, by region, 2017-2030 (USD Million)
    • 5.4.5 Others
      • 5.4.5.1 Market size, by region, 2017-2030 (USD Million)
  • 5.5 Growth Hormone Deficiency
    • 5.5.1 Market size, by region, 2017-2030 (USD Million)
  • 5.6 Diabetes
    • 5.6.1 Market size, by region, 2017-2030 (USD Million)
  • 5.7 Others
    • 5.7.1 Market size, by region, 2017-2030 (USD Million)

Chapter 6 Biosimilars Market, By Manufacturer

  • 6.1 Key segment trends
  • 6.2 Contract Research and Manufacturing Services
    • 6.2.1 Market size, by region, 2017-2030 (USD Million)
  • 6.3 In-house
    • 6.3.1 Market size, by region, 2017-2030 (USD Million)

Chapter 7 Biosimilars Market, By Technology

  • 7.1 Key segment trends
  • 7.2 Recombinant DNA Technology (rDNA technology)
    • 7.2.1 Market size, by region, 2017-2030 (USD Million)
  • 7.3 Monoclonal Antibodies (MAb) Technology
    • 7.3.1 Market size, by region, 2017-2030 (USD Million)

Chapter 8 Biosimilars Market, By Region

  • 8.1 Key regional trends
  • 8.2 North America
    • 8.2.1 Market size, by country, 2017-2030 (USD Million)
    • 8.2.2 Market size, by product, 2017-2030 (USD Million)
      • 8.2.2.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
      • 8.2.2.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.2.2.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
    • 8.2.3 Market size, by application, 2017-2030 (USD Million)
      • 8.2.3.1 Market size, by hematology, 2017-2030 (USD Million)
      • 8.2.3.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.2.3.2.1 Market size, by leukemia, 2017-2030 (USD Million)
      • 8.2.3.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.2.3.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.2.3.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
    • 8.2.4 Market size, by manufacturer, 2017-2030 (USD Million)
    • 8.2.5 Market size, by technology, 2017-2030 (USD Million)
    • 8.2.6 U.S.
      • 8.2.6.1 Market size, by product, 2017-2030 (USD Million)
        • 8.2.6.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.2.6.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.2.6.1.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
      • 8.2.6.2 Market size, by application, 2017-2030 (USD Million)
        • 8.2.6.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.2.6.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.2.6.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.2.6.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.2.6.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.2.6.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.2.6.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.2.6.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.2.7 Canada
      • 8.2.7.1 Market size, by product, 2017-2030 (USD Million)
        • 8.2.7.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.2.7.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.2.7.1.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
      • 8.2.7.2 Market size, by application, 2017-2030 (USD Million)
        • 8.2.7.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.2.7.2.2 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.2.7.2.2.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.2.7.2.2.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.2.7.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.2.7.4 Market size, by technology, 2017-2030 (USD Million)
  • 8.3 Europe
    • 8.3.1 Market size, by country, 2017-2030 (USD Million)
    • 8.3.2 Market size, by product, 2017-2030 (USD Million)
      • 8.3.2.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.2.1.1 Market size, by interferon, 2017-2030 (USD Million)
      • 8.3.2.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.2.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.2.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.2.2.3 Market size, by follitropin, 2017-2030 (USD Million)
    • 8.3.3 Market size, by application, 2017-2030 (USD Million)
      • 8.3.3.1 Market size, by hematology, 2017-2030 (USD Million)
      • 8.3.3.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.3.2.1 Market size, by leukemia, 2017-2030 (USD Million)
      • 8.3.3.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.3.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.3.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
    • 8.3.4 Market size, by manufacturer, 2017-2030 (USD Million)
    • 8.3.5 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.6 Germany
      • 8.3.6.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.6.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.6.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.6.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.6.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.6.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.6.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.6.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.6.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.6.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.6.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.6.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.6.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.6.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.6.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.6.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.7 UK
      • 8.3.7.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.7.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.7.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.7.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.7.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.7.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.7.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.7.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.7.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.7.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.7.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.7.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.7.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.7.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.7.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.7.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.8 France
      • 8.3.8.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.8.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.8.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.8.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.8.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.8.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.8.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.8.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.8.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.8.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.8.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.8.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.8.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.8.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.8.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.8.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.9 Spain
      • 8.3.9.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.9.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.9.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.9.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.9.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.9.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.9.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.9.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.9.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.9.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.9.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.9.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.9.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.9.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.9.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.9.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.10 Italy
      • 8.3.10.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.10.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.10.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.10.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.10.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.10.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.10.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.10.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.10.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.10.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.10.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.10.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.10.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.10.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.10.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.10.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.11 Turkey
      • 8.3.11.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.11.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.11.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.11.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.11.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.11.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.11.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.11.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.11.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.11.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.11.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.11.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.11.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.11.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.11.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.11.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.12 Austria
      • 8.3.12.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.12.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.12.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.12.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.12.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.12.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.12.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.12.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.12.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.12.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.12.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.12.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.12.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.12.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.12.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.12.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.13 Belgium
      • 8.3.13.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.13.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.13.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.13.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.13.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.13.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.13.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.13.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.13.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.13.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.13.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.13.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.13.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.13.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.13.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.13.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.14 Bulgaria
      • 8.3.14.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.14.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.14.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.14.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.14.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.14.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.14.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.14.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.14.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.14.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.14.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.14.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.14.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.14.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.14.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.14.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.15 Czech Republic
      • 8.3.15.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.15.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.15.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.15.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.15.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.15.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.15.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.15.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.15.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.15.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.15.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.15.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.15.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.15.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.15.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.15.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.16 Denmark
      • 8.3.16.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.16.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.16.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.16.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.16.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.16.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.16.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.16.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.16.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.16.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.16.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.16.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.16.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.16.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.16.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.16.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.17 Finland
      • 8.3.17.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.17.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.17.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.17.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.17.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.17.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.17.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.17.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.17.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.17.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.17.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.17.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.17.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.17.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.17.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.17.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.18 Greece
      • 8.3.18.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.18.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.18.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.18.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.18.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.18.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.18.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.18.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.18.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.18.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.18.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.18.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.18.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.18.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.18.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.18.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.19 Hungary
      • 8.3.19.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.19.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.19.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.19.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.19.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.19.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.19.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.19.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.19.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.19.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.19.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.19.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.19.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.19.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.19.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.19.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.20 Ireland
      • 8.3.20.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.20.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.20.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.20.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.20.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.20.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.20.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.20.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.20.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.20.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.20.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.20.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.20.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.20.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.20.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.20.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.21 Netherlands
      • 8.3.21.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.21.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.21.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.21.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.21.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.21.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.21.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.21.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.21.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.21.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.21.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.21.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.21.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.21.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.21.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.21.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.22 Norway
      • 8.3.22.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.22.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.22.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.22.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.22.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.22.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.22.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.22.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.22.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.22.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.22.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.22.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.22.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.22.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.22.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.22.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.23 Romania
      • 8.3.23.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.23.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.23.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.23.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.23.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.23.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.23.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.23.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.23.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.23.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.23.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.23.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.23.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.23.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.23.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.23.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.24 Slovakia
      • 8.3.24.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.24.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.24.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.24.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.24.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.24.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.24.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.24.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.24.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.24.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.24.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.24.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.24.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.24.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.24.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.24.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.25 Slovenia
      • 8.3.25.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.25.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.25.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.25.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.25.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.25.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.25.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.25.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.25.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.25.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.25.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.25.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.25.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.25.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.25.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.25.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.26 Sweden
      • 8.3.26.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.26.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.26.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.26.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.26.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.26.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.26.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.26.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.26.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.26.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.26.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.26.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.26.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.26.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.26.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.26.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.27 Switzerland
      • 8.3.27.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.27.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.27.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.27.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.27.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.27.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.27.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.27.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.27.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.27.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.27.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.27.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.27.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.27.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.27.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.27.4 Market size, by technology, 2017-2030 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Market size, by country, 2017-2030 (USD Million)
    • 8.4.2 Market size, by product, 2017-2030 (USD Million)
      • 8.4.2.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.2.1.1 Market size, by interferon, 2017-2030 (USD Million)
      • 8.4.2.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.2.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.4.2.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.4.2.2.3 Market size, by follitropin, 2017-2030 (USD Million)
    • 8.4.3 Market size, by application, 2017-2030 (USD Million)
      • 8.4.3.1 Market size, by hematology, 2017-2030 (USD Million)
      • 8.4.3.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.3.2.1 Market size, by leukemia, 2017-2030 (USD Million)
      • 8.4.3.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.4.3.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.4.3.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
    • 8.4.4 Market size, by manufacturer, 2017-2030 (USD Million)
    • 8.4.5 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.6 China
      • 8.4.6.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.6.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.6.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.4.6.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.6.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.4.6.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.4.6.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.4.6.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.6.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.4.6.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.6.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.4.6.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.4.6.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.4.6.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.4.6.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.6.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.7 Japan
      • 8.4.7.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.7.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.7.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.7.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.4.7.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
      • 8.4.7.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.7.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.4.7.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.7.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.4.7.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.4.7.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.4.7.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.4.7.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.7.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.8 India
      • 8.4.8.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.8.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.8.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.4.8.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.8.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.4.8.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.4.8.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.4.8.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.8.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.4.8.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.8.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.4.8.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.4.8.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.4.8.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.4.8.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.8.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.9 South Korea
      • 8.4.9.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.9.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.9.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.9.1.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
      • 8.4.9.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.9.2.1 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.9.2.1.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.4.9.2.2 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.4.9.2.2.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.4.9.2.2.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.4.9.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.9.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.10 Australia
      • 8.4.10.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.10.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.10.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.10.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.4.10.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.4.10.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.4.10.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.10.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.4.10.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.10.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.4.10.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.4.10.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.4.10.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.4.10.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.10.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.11 New Zealand
      • 8.4.11.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.11.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.11.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.11.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
      • 8.4.11.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.11.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.4.11.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.11.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
      • 8.4.11.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.11.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.12 Singapore
      • 8.4.12.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.12.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.12.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.12.1.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
      • 8.4.12.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.12.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.4.12.2.2 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.4.12.2.2.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.4.12.2.2.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.4.12.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.12.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.13 Malaysia
      • 8.4.13.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.13.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.13.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.13.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
      • 8.4.13.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.13.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.4.13.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.13.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
      • 8.4.13.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.13.4 Market size, by technology, 2017-2030 (USD Million)

Chapter 9 Company Profiles

  • 9.1 Competitive dashboard, 2021
  • 9.2 Biocon Ltd
    • 9.2.1 Business overview
    • 9.2.2 Financial data
    • 9.2.3 Product landscape
    • 9.2.4 Strategic outlook
    • 9.2.5 SWOT analysis
  • 9.3 Sandoz
    • 9.3.1 Business overview
    • 9.3.2 Financial data
    • 9.3.3 Product landscape
    • 9.3.4 Strategic outlook
    • 9.3.5 SWOT analysis
  • 9.4 Viatris
    • 9.4.1 Business overview
    • 9.4.2 Financial data
    • 9.4.3 Product landscape
    • 9.4.4 Strategic outlook
    • 9.4.5 SWOT analysis
  • 9.5 Bio-Thera Solutions
    • 9.5.1 Business overview
    • 9.5.2 Financial data
    • 9.5.3 Product landscape
    • 9.5.4 Strategic outlook
    • 9.5.5 SWOT analysis
  • 9.6 Pfizer
    • 9.6.1 Business overview
    • 9.6.2 Financial data
    • 9.6.3 Product landscape
    • 9.6.4 Strategic outlook
    • 9.6.5 SWOT analysis
  • 9.7 Dr. Reddy's Laboratories
    • 9.7.1 Business overview
    • 9.7.2 Financial data
    • 9.7.3 Product landscape
    • 9.7.4 Strategic outlook
    • 9.7.5 SWOT analysis
  • 9.8 Amgen Inc.
    • 9.8.1 Business overview
    • 9.8.2 Financial data
    • 9.8.3 Product landscape
    • 9.8.4 Strategic outlook
    • 9.8.5 SWOT analysis
  • 9.9 Teva Pharmaceuticals
    • 9.9.1 Business overview
    • 9.9.2 Financial data
    • 9.9.3 Product landscape
    • 9.9.4 Strategic outlook
    • 9.9.5 SWOT analysis
  • 9.10 Fresenius Kabi
    • 9.10.1 Business overview
    • 9.10.2 Financial data
    • 9.10.3 Product landscape
    • 9.10.4 Strategic outlook
    • 9.10.5 SWOT analysis
  • 9.11 Coherus Biosciences
    • 9.11.1 Business overview
    • 9.11.2 Financial data
    • 9.11.3 Product landscape
    • 9.11.4 Strategic outlook
    • 9.11.5 SWOT analysis
  • 9.12 Apobiologix
    • 9.12.1 Business overview
    • 9.12.2 Financial data
    • 9.12.3 Product landscape
    • 9.12.4 Strategic outlook
    • 9.12.5 SWOT analysis
  • 9.13 Biocad
    • 9.13.1 Business overview
    • 9.13.2 Financial data
    • 9.13.3 Product landscape
    • 9.13.4 Strategic outlook
    • 9.13.5 SWOT analysis
  • 9.14 Intas Pharma
    • 9.14.1 Business overview
    • 9.14.2 Financial data
    • 9.14.3 Product landscape
    • 9.14.4 Strategic outlook
    • 9.14.5 SWOT analysis
  • 9.15 Reliance Life Sciences
    • 9.15.1 Business overview
    • 9.15.2 Financial data
    • 9.15.3 Product landscape
    • 9.15.4 Strategic outlook
    • 9.15.5 SWOT analysis
  • 9.16 Celltrion
    • 9.16.1 Business overview
    • 9.16.2 Financial data
    • 9.16.3 Product landscape
    • 9.16.4 Strategic outlook
    • 9.16.5 SWOT analysis
  • 9.17 Zydus Cadila
    • 9.17.1 Business overview
    • 9.17.2 Financial data
    • 9.17.3 Product landscape
    • 9.17.4 Strategic outlook
    • 9.17.5 SWOT analysis
  • 9.18 Lupin Pharma
    • 9.18.1 Business overview
    • 9.18.2 Financial data
    • 9.18.3 Product landscape
    • 9.18.4 Strategic outlook
    • 9.18.5 SWOT analysis
  • 9.19 Samsung Bioepis
    • 9.19.1 Business overview
    • 9.19.2 Financial data
    • 9.19.3 Product landscape
    • 9.19.4 Strategic outlook
    • 9.19.5 SWOT analysis
Back to Top
전화 문의
F A Q